Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression.

Wang Z, Lecane PS, Thiemann P, Fan Q, Cortez C, Ma X, Tonev D, Miles D, Naumovski L, Miller RA, Magda D, Cho DG, Sessler JL, Pike BL, Yeligar SM, Karaman MW, Hacia JG.

Mol Cancer. 2007 Jan 19;6:9.

2.

Tumor localization and antitumor efficacy of novel sapphyrin compounds.

Naumovski L, Sirisawad M, Lecane P, Chen J, Ramos J, Wang Z, Cortez C, Magda D, Thiemann P, Boswell G, Miles D, Cho DG, Sessler JL, Miller R.

Mol Cancer Ther. 2006 Nov;5(11):2798-805.

3.

Sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show in vivo antitumor activity.

Naumovski L, Ramos J, Sirisawad M, Chen J, Thiemann P, Lecane P, Magda D, Wang Z, Cortez C, Boswell G, Gyu Cho D, Sessler J, Miller R.

Mol Cancer Ther. 2005 Jun;4(6):968-76.

4.

Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells.

Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S.

Int J Mol Med. 2009 Jul;24(1):45-50.

PMID:
19513533
5.

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.

Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.

Cancer Chemother Pharmacol. 2009 Jun;64(1):53-65. doi: 10.1007/s00280-008-0850-3. Epub 2008 Oct 19.

PMID:
18931998
6.

Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.

Wang R, Wang X, Li B, Lin F, Dong K, Gao P, Zhang HZ.

Breast Cancer Res Treat. 2009 Sep;117(1):45-54. doi: 10.1007/s10549-008-0163-6. Epub 2008 Sep 13.

PMID:
18791823
7.

Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.

De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S.

Cancer Res. 2007 Jun 1;67(11):5408-17.

8.

p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.

Katiyar SK, Meeran SM, Katiyar N, Akhtar S.

Mol Carcinog. 2009 Jan;48(1):24-37. doi: 10.1002/mc.20453.

PMID:
18459128
9.
10.

Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells.

Minelli A, Bellezza I, Tucci A, Rambotti MG, Conte C, Culig Z.

Prostate. 2009 Apr 1;69(5):538-47. doi: 10.1002/pros.20900.

PMID:
19107848
11.

Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.

Bracker TU, Sommer A, Fichtner I, Faus H, Haendler B, Hess-Stumpp H.

Int J Oncol. 2009 Oct;35(4):909-20.

PMID:
19724929
12.

Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).

Vinodhkumar R, Song YS, Ravikumar V, Ramakrishnan G, Devaki T.

Chem Biol Interact. 2007 Feb 20;165(3):220-9. Epub 2007 Jan 22.

PMID:
17240363
13.
14.

Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.

Engel D, Nudelman A, Tarasenko N, Levovich I, Makarovsky I, Sochotnikov S, Tarasenko I, Rephaeli A.

J Med Chem. 2008 Jan 24;51(2):314-23. doi: 10.1021/jm7009827. Epub 2007 Dec 29.

PMID:
18163551
15.

Glioma cells on the run - the migratory transcriptome of 10 human glioma cell lines.

Demuth T, Rennert JL, Hoelzinger DB, Reavie LB, Nakada M, Beaudry C, Nakada S, Anderson EM, Henrichs AN, McDonough WS, Holz D, Joy A, Lin R, Pan KH, Lih CJ, Cohen SN, Berens ME.

BMC Genomics. 2008 Jan 29;9:54. doi: 10.1186/1471-2164-9-54.

16.

In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.

Ni J, Mai T, Pang ST, Haque I, Huang K, DiMaggio MA, Xie S, James NS, Kasi D, Chemler SR, Yeh S.

Clin Cancer Res. 2009 Feb 1;15(3):898-906. doi: 10.1158/1078-0432.CCR-08-1087.

17.

Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.

Zhang Y, Ma Y, Lu HP, Gao JH, Liang CS, Liu CZ, Zou JT, Wang HQ.

Chin Med J (Engl). 2008 Nov 20;121(22):2284-9.

PMID:
19080333
18.

Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.

Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R, Wang H.

Prostate. 2008 Jun 1;68(8):809-19. doi: 10.1002/pros.20742.

PMID:
18324646
19.

Inhibition of tumor growth by endohedral metallofullerenol nanoparticles optimized as reactive oxygen species scavenger.

Yin JJ, Lao F, Meng J, Fu PP, Zhao Y, Xing G, Gao X, Sun B, Wang PC, Chen C, Liang XJ.

Mol Pharmacol. 2008 Oct;74(4):1132-40. doi: 10.1124/mol.108.048348. Epub 2008 Jul 17.

20.

Supplemental Content

Support Center